MIF and prostate cancer: Significantly increased levels of MIF were detected in plasma from patients with ovarian cancer (median 9.6 ng/ml), prostate cancer (median 8.9 ng/ml), breast cancer (median 8.4 ng/ml), head and neck cancer (median 8.3 ng/ml) and renal cell carcinoma (median 10.1 ng/ml) (Figure 1B).